结肠癌肝转移动脉灌注化疗与静脉化疗疗效评价

目的评价经肝动脉灌注化疗与静脉化疗治疗结肠癌肝转移的疗效。方法64例结肠癌肝转移患者随机分为肝动脉灌注化疗组和静脉化疗组。两组均采用FAM方案化疗。分析两组的CR、PR、RR及1、2、3年生存率。结果肝动脉灌注化疗组的CR、PR、RR显著高于静脉化疗组（20％vs.8.6％,47.5%vs.22.3％,67.5％vs.31.7％,P<0.05）；肝动脉灌注化疗组的1、2、3年生存率也显著高于静脉化疗组（84.4％vs.21.9％,59.4％vs.6.3％,34.4％vs.0％,P<0.05）。结论肝动脉灌注化疗治疗结肠癌肝转移优于静脉化疗。

Evaluation of Therapeutic Effect of Hepatic Arterial Infusion or Venous Chemotherapy in Treatment of Liver Metastasis from Colon Cancer

Objective To evaluate the therapeutic effect of hepatic arterial infusion and venous chemotherapy in the treatment of patients with liver metastases from colon cancer.Methods Sixty four patients with liver metastases from colon cancer were randomly divided into hepatic arterial infusion (HAI) group and venous chemotherapy (VC) group. FAM chemtherapy protocol was used in both two groups. CR, PR, RR and 1 , 2 , 3 year survival rates in two groups were analyzed.Results CR, PR, RR in HAI group was significantly higher than that in VC group (20% vs. 8.6%; 47.5% vs. 22.3%; 67.5% vs. 31.7%, P <0.05, respectively). 1 ,2 , and 3 year survival rates in HAI group were also significantly higher than those in VC group (84.4% vs. 21.9%; 59.4% vs. 6.3%; 34.4% vs. 0%, P <0.05, respectively).Conclusion HAI was superior to VC group in the treatment of liver metastases from colon cancer.